Erdheim-Chester disease harboring the BRAF V600E mutation

J Clin Oncol. 2012 Nov 10;30(32):e331-2. doi: 10.1200/JCO.2012.43.2260. Epub 2012 Sep 24.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Benzamides
  • Biomarkers / metabolism
  • Erdheim-Chester Disease / diagnosis*
  • Erdheim-Chester Disease / drug therapy
  • Erdheim-Chester Disease / genetics*
  • Erdheim-Chester Disease / metabolism
  • Glutamic Acid
  • Humans
  • Imatinib Mesylate
  • Immunohistochemistry
  • Interferon-alpha / administration & dosage
  • Male
  • Middle Aged
  • Mutation*
  • Piperazines / administration & dosage
  • Prednisolone / administration & dosage
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyrimidines / administration & dosage
  • Receptor, Platelet-Derived Growth Factor beta / metabolism
  • Valine

Substances

  • Benzamides
  • Biomarkers
  • Interferon-alpha
  • Piperazines
  • Pyrimidines
  • Glutamic Acid
  • Imatinib Mesylate
  • Prednisolone
  • Receptor, Platelet-Derived Growth Factor beta
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Valine